University of Nottingham CiC#6 : accelerating translation of novel, early-stage, interdisciplinary, biomedical research
Lead Research Organisation:
University of Nottingham
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Allen CM
(2021)
Magnetoencephalography abnormalities in adult mild traumatic brain injury: A systematic review.
in NeuroImage. Clinical
Begitt A
(2023)
A family-wide assessment of latent STAT transcription factor interactions reveals divergent dimer repertoires
in Journal of Biological Chemistry
Hughes J
(2022)
Towards Development of a Non-Toxigenic Clostridioides difficile Oral Spore Vaccine against Toxigenic C. difficile.
in Pharmaceutics
Karyal C
(2021)
Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile.
in Microorganisms
Koido M
(2020)
Polygenic architecture informs potential vulnerability to drug-induced liver injury.
in Nature medicine
Rier L
(2021)
Mild traumatic brain injury impairs the coordination of intrinsic and motor-related neural dynamics.
in NeuroImage. Clinical
| Description | National consensus document on mild traumatic brain injury |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://spiral.imperial.ac.uk/handle/10044/1/81286 |
| Description | Novel delivery routes for c.difficile vaccines |
| Amount | £50,000 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 06/2021 |
| Description | Splitting STAT Dimers to Understand Interferon Balance: A Strategy to Dissociate Beneficial and Detrimental Interferon Effects in Infection? |
| Amount | £715,073 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2021 |
| End | 05/2024 |
| Description | Development and initial validation of the next generation newborn resuscitation monitoring device to improve outcomes for high-risk infants |
| Organisation | Surepulse Medical Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Our co-funded clinical research fellow supports study setup/running and data collection, our research nurse assists training, patient recruitment and data collection and we also supply consumables . Furthermore, our leadership team provide the medical and some associated engineering technical expertise. |
| Collaborator Contribution | Sure Pulse medical have provided funding for a Clinical research fellow (£34K), and in-kind support to provide access to an engineer (0.2wte £8.3K) |
| Impact | Project is still in progress. Outcomes not yet realised. Collaboration is multi-disciplinary, |
| Start Year | 2018 |
| Title | THERAPEUTIC COMPOUNDS |
| Description | The invention provides a product which is a compound of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof: (I) wherein: X is selected from: hydrogen; a methyl group which is optionally substituted, wherein any substituent groups present are independently selected from hydroxyl, halo and NR'2, where each R' is independently selected from hydrogen and methyl; and an ethyl group which is either unsubstituted or is substituted with from one to five F substituent groups; Y is selected from: hydrogen; a methyl group which is optionally substituted, wherein any substituent groups present are independently selected from hydroxyl, halo and NR'2, where each R' is independently selected from hydrogen and methyl; and an ethyl group which is either unsubstituted or is substituted with from one to five F substituent groups; RA is hydrogen, or is a C1-2 alkyl group which is optionally substituted, wherein any substituent groups present are independently selected from hydroxyl, halo and NR'2, where each R' is independently selected from hydrogen and methyl. |
| IP Reference | WO2020240199 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | None as yet |
| Company Name | NEUROTHERAPEUTICS LTD |
| Description | https://www.nottingham.ac.uk/news/spin-out-company-launched-deliver-wrist-device-control-tourettes |
| Year Established | 2019 |
| Impact | https://www.nottingham.ac.uk/news/spin-out-company-launched-deliver-wrist-device-control-tourettes |